Results 61 to 70 of about 676,789 (144)

A Picomolar MBP-Binding Nanobody for Target Enrichment and Modular Complex Engineering

ACS Bio & Med Chem Au
Monica Chinellato, Elisa Franzin, Filippo Vascon, Paul-Albert Koenig, Florian I. Schmidt, Patrizia Pontisso, Laura Cendron   +6 more
doaj   +1 more source

Characterization of Anti-Canine PD-1 Antibodies. [PDF]

Cells
Hartman CJ, Sergent P, Zimmermann ABE, Chávez-Alexander-Anderson OR, Perez Alonso LA, Lines L, Pinto-Cárdenas JC, Luna Dávalos D, Schmoker AM, Palisoul SM, Vom Berg J, Ge X, Rothstein JL, Ackerman ME, Fiering S, Noelle RJ, Arias-Pulido H.   +16 more
europepmc   +1 more source

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial. [PDF]

J Immunother Cancer
Ulas EB, Purcell ND, Houda I, Hashemi SMS, Veltman J, Daniels JMA, Fransen MF, Radonic T, Beeloo LR, van Rossum PSN, van Maldegem F, Barlo N, Disselhorst M, van Laren M, Tiemessen MA, Tarasevych S, van Haarst JM, van Tilburg P, Kunst PWA, Moons-Pasic A, Oprea-Lager DE, Meijboom LJ, Bouwhuis N, de Gruijl TD, Senan S, Schneiders FL, Bahce I.   +26 more
europepmc   +1 more source

PD-1 targets CD28 [PDF]

Nature Immunology, 2017
openaire   +2 more sources

The Application of PD-1 Inhibitors in Immunotherapy for Glioblastoma. [PDF]

FASEB J
Dong MZ, Cui M, Qu LZ, Che HY, Guan HJ.
europepmc   +1 more source

Retraction: Imbalance of Circulating Monocyte Subsets and PD-1 Dysregulation in Q Fever Endocarditis: The Role of IL-10 in PD-1 Modulation. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

A bibliometric analysis of resistance to PD-1/PD-L1 inhibitors. [PDF]

Front Immunol
Miao L, Jiang Z.
europepmc   +1 more source

Effect of CXCR5, PD-1 and ICOS on B-cell responses and relevance to myasthenia gravis. [PDF]

Clin Transl Immunology
Çebi M, Çakar A, Durmuş H, Parman Y, Saruhan-Direskeneli G.   +4 more
europepmc   +1 more source

PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy. [PDF]

Oncoimmunology
Yamaguchi A, Suzuki H, Takasuga S, Tatematsu M, Fuchimukai A, Endo T, Kaya H, Morishita A, Seki S, Imai K, Ebihara T.   +10 more
europepmc   +1 more source

JAK inhibition in PD-1 immunotherapy and tumor microenvironment. [PDF]

Front Immunol
Liu Z, Liu J, Chu H, Lu Z, Xu S, Qin Y, Zhao L, Zhang C.   +7 more
europepmc   +1 more source